F M Investments LLC Takes $1.19 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

F M Investments LLC purchased a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 64,660 shares of the biopharmaceutical company's stock, valued at approximately $1,187,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC raised its holdings in shares of ACADIA Pharmaceuticals by 380.3% in the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after purchasing an additional 1,966,607 shares in the last quarter. Barclays PLC boosted its holdings in shares of ACADIA Pharmaceuticals by 126.2% in the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock valued at $4,269,000 after buying an additional 154,854 shares in the last quarter. Burney Co. purchased a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $6,953,000. Proficio Capital Partners LLC acquired a new stake in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $272,000. Finally, State Street Corp increased its position in shares of ACADIA Pharmaceuticals by 3.0% during the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company's stock worth $91,878,000 after purchasing an additional 173,084 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ACAD shares. Guggenheim downgraded ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. Morgan Stanley reissued an "equal weight" rating and issued a $20.00 target price on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "hold" rating and a $22.00 price objective on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $23.93.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 2,708 shares of the business's stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total value of $40,132.56. Following the transaction, the executive vice president now directly owns 59,456 shares in the company, valued at $881,137.92. The trade was a 4.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares in the company, valued at $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,169 shares of company stock worth $242,686 in the last ninety days. Insiders own 28.30% of the company's stock.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ ACAD traded up $0.02 during mid-day trading on Thursday, reaching $14.59. The company's stock had a trading volume of 346,735 shares, compared to its average volume of 1,848,354. The stock has a market capitalization of $2.43 billion, a P/E ratio of 18.77 and a beta of 0.54. ACADIA Pharmaceuticals Inc. has a 1-year low of $13.40 and a 1-year high of $20.68. The stock has a 50-day moving average of $17.32 and a two-hundred day moving average of $16.93.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.